Opinion of the Transparency Council – loratadine
At its meeting on 2 June 2025, the Transparency Council adopted opinion No. 96/2025 on concerning the inclusion of drugs containing the active substance loratadine in the reimbursement scheme for indications, dosages, or routes of administration other than those specified in the Summary of Product Characteristics, i.e., food allergy; anaphylactic reaction